SF0034

SF0034 is a novel small molecule drug developed as a potent and selective activator of neuronal potassium channels, specifically targeting KCNQ2 and KCNQ3 (Kv7.2/7.3) subunits. It is structurally related to retigabine but incorporates an additional fluorine atom, which confers greater selectivity and potency for KCNQ2/3 channels while avoiding activity at other KCNQ family members (KCNQ4, KCNQ5). This selectivity reduces the risk of side effects associated with less specific channel openers like retigabine[1][3][5][6][7]. Preclinical studies have demonstrated that SF0034 is more effective than retigabine in suppressing seizures in animal models of epilepsy and can prevent the development of tinnitus in mice[1][5][6][7]. The compound acts by shifting the voltage dependence of channel opening to more negative potentials, thereby stabilizing neuronal excitability and providing an anticonvulsant effect[7]. SciFluor Life Sciences developed SF0034 as a clinical candidate for epilepsy (primary indication) and tinnitus (secondary indication), aiming to offer improved efficacy with fewer adverse effects compared to existing therapies[1][3].